9 min
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy OncLive® On Air
-
- Health & Fitness
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
9 min